Inventera's nanoparticle platform, composed of biocompatible iron (Fe) and carbohydrates, is engineered for both safety and performance. Through our proprietary nanosynthesis and surface coating technologies, we have significantly enhanced the contrast effects and resolution in MRI imaging. A key feature of our platform is its ability to ensure safe excretion, preventing long-term accumulation in the body.

​

Building on this foundation, we are developing the world’s first iron-based T1-MRI contrast agents (First-in-Class), aimed at addressing high-demand indications that are challenging to diagnose with existing MRI contrast agents. Our pipeline targets critical areas such as the articular system, lymphatic vessels, and the pancreatic and biliary systems, offering improved diagnostic accuracy in these fields.

​

Our goal is to commercialize high-performance contrast agents that enable the early and precise diagnosis of diseases where gadolinium-based agents have shown limitations in safety and efficacy. With this breakthrough technology, Inventera is positioned to transform the MRI contrast agent market, meeting unmet medical needs and delivering solutions that set new standards for patient care.​ With these innovations, Inventera is contributing to shape the future of MRI diagnostics, providing improved accuracy and safety for patients.